nodes	percent_of_prediction	percent_of_DWPC	metapath
Epinephrine—SLC22A5—Dactinomycin—kidney cancer	0.104	0.218	CbGbCtD
Epinephrine—SLC22A2—Vinblastine—kidney cancer	0.0623	0.131	CbGbCtD
Epinephrine—CYP3A4—Everolimus—kidney cancer	0.0489	0.102	CbGbCtD
Epinephrine—CYP1A2—Pazopanib—kidney cancer	0.0331	0.0693	CbGbCtD
Epinephrine—CYP3A4—Temsirolimus—kidney cancer	0.033	0.0692	CbGbCtD
Epinephrine—CYP2C9—Capecitabine—kidney cancer	0.0311	0.0652	CbGbCtD
Epinephrine—CYP1A2—Erlotinib—kidney cancer	0.0236	0.0495	CbGbCtD
Epinephrine—CYP2C9—Paclitaxel—kidney cancer	0.0195	0.0408	CbGbCtD
Epinephrine—CYP1A2—Sorafenib—kidney cancer	0.0192	0.0402	CbGbCtD
Epinephrine—CYP3A4—Pazopanib—kidney cancer	0.0174	0.0363	CbGbCtD
Epinephrine—CYP2C9—Sorafenib—kidney cancer	0.0173	0.0362	CbGbCtD
Epinephrine—CYP3A4—Erlotinib—kidney cancer	0.0124	0.0259	CbGbCtD
Epinephrine—CYP3A4—Paclitaxel—kidney cancer	0.0113	0.0237	CbGbCtD
Epinephrine—SLC22A2—nephron—kidney cancer	0.0106	0.148	CbGeAlD
Epinephrine—CYP3A4—Sorafenib—kidney cancer	0.0101	0.0211	CbGbCtD
Epinephrine—CYP3A4—Vinblastine—kidney cancer	0.00994	0.0208	CbGbCtD
Epinephrine—CYP3A4—Vincristine—kidney cancer	0.00977	0.0205	CbGbCtD
Epinephrine—CYP3A4—Sunitinib—kidney cancer	0.00816	0.0171	CbGbCtD
Epinephrine—CYP3A4—Doxorubicin—kidney cancer	0.00611	0.0128	CbGbCtD
Epinephrine—SLC22A5—Temsirolimus—Everolimus—kidney cancer	0.00469	1	CbGdCrCtD
Epinephrine—PAH—renal system—kidney cancer	0.00443	0.062	CbGeAlD
Epinephrine—PAH—kidney—kidney cancer	0.00428	0.06	CbGeAlD
Epinephrine—CYP1A2—urine—kidney cancer	0.00378	0.0529	CbGeAlD
Epinephrine—CYP2C9—urine—kidney cancer	0.00359	0.0502	CbGeAlD
Epinephrine—ADRBK1—renal system—kidney cancer	0.00338	0.0473	CbGeAlD
Epinephrine—ADRBK1—kidney—kidney cancer	0.00327	0.0458	CbGeAlD
Epinephrine—ADRBK1—gonad—kidney cancer	0.00303	0.0425	CbGeAlD
Epinephrine—CYP3A4—urine—kidney cancer	0.00273	0.0383	CbGeAlD
Epinephrine—Dipivefrin—ACHE—kidney cancer	0.00234	0.339	CrCbGaD
Epinephrine—SLC22A2—nephron tubule—kidney cancer	0.00229	0.032	CbGeAlD
Epinephrine—SLC22A2—renal system—kidney cancer	0.00208	0.0291	CbGeAlD
Epinephrine—SLC22A2—kidney—kidney cancer	0.00201	0.0282	CbGeAlD
Epinephrine—ADRA1B—renal system—kidney cancer	0.00199	0.0279	CbGeAlD
Epinephrine—SLC22A2—cortex of kidney—kidney cancer	0.00196	0.0274	CbGeAlD
Epinephrine—ADRA1B—kidney—kidney cancer	0.00192	0.0269	CbGeAlD
Epinephrine—Isoprenaline—MAPK1—kidney cancer	0.00163	0.237	CrCbGaD
Epinephrine—SLC22A1—renal system—kidney cancer	0.00147	0.0206	CbGeAlD
Epinephrine—SLC22A1—kidney—kidney cancer	0.00142	0.0199	CbGeAlD
Epinephrine—Dipivefrin—BCHE—kidney cancer	0.00138	0.2	CrCbGaD
Epinephrine—ADRB1—cardiac atrium—kidney cancer	0.00127	0.0177	CbGeAlD
Epinephrine—Terbutaline—BCHE—kidney cancer	0.00119	0.173	CrCbGaD
Epinephrine—ADRA2C—nephron tubule—kidney cancer	0.00117	0.0164	CbGeAlD
Epinephrine—SLC22A5—nephron tubule—kidney cancer	0.00112	0.0157	CbGeAlD
Epinephrine—ADRA1A—renal system—kidney cancer	0.00112	0.0157	CbGeAlD
Epinephrine—ADRA2C—renal system—kidney cancer	0.00106	0.0149	CbGeAlD
Epinephrine—ADRA2C—kidney—kidney cancer	0.00103	0.0144	CbGeAlD
Epinephrine—SLC22A5—renal system—kidney cancer	0.00102	0.0143	CbGeAlD
Epinephrine—ADRA2C—cortex of kidney—kidney cancer	0.001	0.0141	CbGeAlD
Epinephrine—SLC22A5—kidney—kidney cancer	0.000986	0.0138	CbGeAlD
Epinephrine—SLC22A5—cortex of kidney—kidney cancer	0.00096	0.0135	CbGeAlD
Epinephrine—ADRA2C—cardiac atrium—kidney cancer	0.000954	0.0134	CbGeAlD
Epinephrine—CYP1A2—renal system—kidney cancer	0.000924	0.013	CbGeAlD
Epinephrine—SLC22A5—cardiac atrium—kidney cancer	0.000914	0.0128	CbGeAlD
Epinephrine—ADRA2A—cortex of kidney—kidney cancer	0.0008	0.0112	CbGeAlD
Epinephrine—ADRA2A—gonad—kidney cancer	0.000762	0.0107	CbGeAlD
Epinephrine—ADRA2A—cardiac atrium—kidney cancer	0.000761	0.0107	CbGeAlD
Epinephrine—Lightheadedness—Paclitaxel—kidney cancer	0.000717	0.00308	CcSEcCtD
Epinephrine—Hypoaesthesia—Vinblastine—kidney cancer	0.000716	0.00308	CcSEcCtD
Epinephrine—Chest pain—Temsirolimus—kidney cancer	0.000714	0.00307	CcSEcCtD
Epinephrine—Hypoaesthesia—Everolimus—kidney cancer	0.000713	0.00306	CcSEcCtD
Epinephrine—Hallucination—Everolimus—kidney cancer	0.000713	0.00306	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Temsirolimus—kidney cancer	0.000709	0.00305	CcSEcCtD
Epinephrine—Cerebrovascular accident—Gemcitabine—kidney cancer	0.000709	0.00304	CcSEcCtD
Epinephrine—Haemoglobin—Erlotinib—kidney cancer	0.000695	0.00299	CcSEcCtD
Epinephrine—Haemorrhage—Erlotinib—kidney cancer	0.000692	0.00297	CcSEcCtD
Epinephrine—Acute coronary syndrome—Sorafenib—kidney cancer	0.000683	0.00294	CcSEcCtD
Epinephrine—Hypertension—Pazopanib—kidney cancer	0.000682	0.00293	CcSEcCtD
Epinephrine—Renal failure—Sorafenib—kidney cancer	0.000681	0.00293	CcSEcCtD
Epinephrine—Myocardial infarction—Sorafenib—kidney cancer	0.00068	0.00292	CcSEcCtD
Epinephrine—Hyperglycaemia—Sunitinib—kidney cancer	0.000675	0.0029	CcSEcCtD
Epinephrine—Chest pain—Pazopanib—kidney cancer	0.000673	0.00289	CcSEcCtD
Epinephrine—Nervous system disorder—Temsirolimus—kidney cancer	0.000671	0.00288	CcSEcCtD
Epinephrine—CYP3A4—renal system—kidney cancer	0.000669	0.00937	CbGeAlD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Pazopanib—kidney cancer	0.000668	0.00287	CcSEcCtD
Epinephrine—Flushing—Everolimus—kidney cancer	0.000665	0.00286	CcSEcCtD
Epinephrine—Skin disorder—Temsirolimus—kidney cancer	0.000665	0.00286	CcSEcCtD
Epinephrine—Acute coronary syndrome—Sunitinib—kidney cancer	0.000658	0.00282	CcSEcCtD
Epinephrine—Blood pressure increased—Capecitabine—kidney cancer	0.000657	0.00282	CcSEcCtD
Epinephrine—Renal failure—Sunitinib—kidney cancer	0.000656	0.00282	CcSEcCtD
Epinephrine—CYP3A4—kidney—kidney cancer	0.000647	0.00906	CbGeAlD
Epinephrine—Nervous system disorder—Pazopanib—kidney cancer	0.000633	0.00272	CcSEcCtD
Epinephrine—Hypokalaemia—Gemcitabine—kidney cancer	0.000632	0.00272	CcSEcCtD
Epinephrine—Mental disorder—Everolimus—kidney cancer	0.000628	0.0027	CcSEcCtD
Epinephrine—Skin exfoliation—Capecitabine—kidney cancer	0.000628	0.0027	CcSEcCtD
Epinephrine—Skin disorder—Pazopanib—kidney cancer	0.000627	0.00269	CcSEcCtD
Epinephrine—Haemoglobin—Sorafenib—kidney cancer	0.000625	0.00269	CcSEcCtD
Epinephrine—Erythema—Everolimus—kidney cancer	0.000624	0.00268	CcSEcCtD
Epinephrine—Hyperhidrosis—Pazopanib—kidney cancer	0.000624	0.00268	CcSEcCtD
Epinephrine—Haemorrhage—Sorafenib—kidney cancer	0.000622	0.00267	CcSEcCtD
Epinephrine—Insomnia—Temsirolimus—kidney cancer	0.000619	0.00266	CcSEcCtD
Epinephrine—Arrhythmia—Erlotinib—kidney cancer	0.000618	0.00265	CcSEcCtD
Epinephrine—Renal impairment—Paclitaxel—kidney cancer	0.000611	0.00262	CcSEcCtD
Epinephrine—Somnolence—Temsirolimus—kidney cancer	0.000609	0.00262	CcSEcCtD
Epinephrine—Mental disorder—Erlotinib—kidney cancer	0.000606	0.0026	CcSEcCtD
Epinephrine—Erythema—Erlotinib—kidney cancer	0.000602	0.00259	CcSEcCtD
Epinephrine—Haemoglobin—Sunitinib—kidney cancer	0.000602	0.00259	CcSEcCtD
Epinephrine—Haemorrhage—Sunitinib—kidney cancer	0.000599	0.00257	CcSEcCtD
Epinephrine—Hypoglycaemia—Paclitaxel—kidney cancer	0.000596	0.00256	CcSEcCtD
Epinephrine—Hypoaesthesia—Sunitinib—kidney cancer	0.000596	0.00256	CcSEcCtD
Epinephrine—Cerebrovascular accident—Paclitaxel—kidney cancer	0.000593	0.00255	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Temsirolimus—kidney cancer	0.000591	0.00254	CcSEcCtD
Epinephrine—Insomnia—Pazopanib—kidney cancer	0.000583	0.00251	CcSEcCtD
Epinephrine—Paraesthesia—Pazopanib—kidney cancer	0.000579	0.00249	CcSEcCtD
Epinephrine—Flushing—Sorafenib—kidney cancer	0.000578	0.00248	CcSEcCtD
Epinephrine—Agitation—Everolimus—kidney cancer	0.000574	0.00246	CcSEcCtD
Epinephrine—Somnolence—Pazopanib—kidney cancer	0.000573	0.00246	CcSEcCtD
Epinephrine—Ventricular arrhythmia—Doxorubicin—kidney cancer	0.000573	0.00246	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Pazopanib—kidney cancer	0.000557	0.00239	CcSEcCtD
Epinephrine—Acute coronary syndrome—Vincristine—kidney cancer	0.000556	0.00239	CcSEcCtD
Epinephrine—Arrhythmia—Sorafenib—kidney cancer	0.000556	0.00239	CcSEcCtD
Epinephrine—Flushing—Sunitinib—kidney cancer	0.000556	0.00239	CcSEcCtD
Epinephrine—Myocardial infarction—Vincristine—kidney cancer	0.000553	0.00238	CcSEcCtD
Epinephrine—Palpitations—Everolimus—kidney cancer	0.000552	0.00237	CcSEcCtD
Epinephrine—Mental disorder—Sorafenib—kidney cancer	0.000545	0.00234	CcSEcCtD
Epinephrine—Erythema—Sorafenib—kidney cancer	0.000542	0.00233	CcSEcCtD
Epinephrine—Hyperglycaemia—Gemcitabine—kidney cancer	0.000541	0.00233	CcSEcCtD
Epinephrine—Hypertension—Vinblastine—kidney cancer	0.000541	0.00232	CcSEcCtD
Epinephrine—Sweating—Vincristine—kidney cancer	0.000541	0.00232	CcSEcCtD
Epinephrine—Necrosis—Doxorubicin—kidney cancer	0.00054	0.00232	CcSEcCtD
Epinephrine—Hypertension—Everolimus—kidney cancer	0.000539	0.00231	CcSEcCtD
Epinephrine—Arrhythmia—Sunitinib—kidney cancer	0.000535	0.0023	CcSEcCtD
Epinephrine—Chest pain—Everolimus—kidney cancer	0.000531	0.00228	CcSEcCtD
Epinephrine—Hypokalaemia—Paclitaxel—kidney cancer	0.000529	0.00227	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.000528	0.00227	CcSEcCtD
Epinephrine—Acute coronary syndrome—Gemcitabine—kidney cancer	0.000528	0.00227	CcSEcCtD
Epinephrine—Renal failure—Gemcitabine—kidney cancer	0.000526	0.00226	CcSEcCtD
Epinephrine—Flushing—Dactinomycin—kidney cancer	0.000526	0.00226	CcSEcCtD
Epinephrine—Myocardial infarction—Gemcitabine—kidney cancer	0.000525	0.00225	CcSEcCtD
Epinephrine—Mental disorder—Sunitinib—kidney cancer	0.000525	0.00225	CcSEcCtD
Epinephrine—Erythema—Sunitinib—kidney cancer	0.000521	0.00224	CcSEcCtD
Epinephrine—Sweating—Gemcitabine—kidney cancer	0.000513	0.0022	CcSEcCtD
Epinephrine—Chest pain—Erlotinib—kidney cancer	0.000513	0.0022	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.000509	0.00219	CcSEcCtD
Epinephrine—Hallucination—Vincristine—kidney cancer	0.000504	0.00216	CcSEcCtD
Epinephrine—Hypoaesthesia—Vincristine—kidney cancer	0.000504	0.00216	CcSEcCtD
Epinephrine—Renal impairment—Capecitabine—kidney cancer	0.000501	0.00215	CcSEcCtD
Epinephrine—Nervous system disorder—Everolimus—kidney cancer	0.000499	0.00215	CcSEcCtD
Epinephrine—Tachycardia—Everolimus—kidney cancer	0.000497	0.00214	CcSEcCtD
Epinephrine—Skin disorder—Everolimus—kidney cancer	0.000495	0.00213	CcSEcCtD
Epinephrine—Erythema—Dactinomycin—kidney cancer	0.000493	0.00212	CcSEcCtD
Epinephrine—Hyperhidrosis—Everolimus—kidney cancer	0.000492	0.00212	CcSEcCtD
Epinephrine—Sweating increased—Paclitaxel—kidney cancer	0.00049	0.0021	CcSEcCtD
Epinephrine—Cerebrovascular accident—Capecitabine—kidney cancer	0.000487	0.00209	CcSEcCtD
Epinephrine—Extravasation—Doxorubicin—kidney cancer	0.000486	0.00209	CcSEcCtD
Epinephrine—Haemoglobin—Gemcitabine—kidney cancer	0.000483	0.00207	CcSEcCtD
Epinephrine—Nervous system disorder—Erlotinib—kidney cancer	0.000482	0.00207	CcSEcCtD
Epinephrine—Haemorrhage—Gemcitabine—kidney cancer	0.00048	0.00206	CcSEcCtD
Epinephrine—Skin disorder—Erlotinib—kidney cancer	0.000477	0.00205	CcSEcCtD
Epinephrine—Ventricular extrasystoles—Doxorubicin—kidney cancer	0.000469	0.00202	CcSEcCtD
Epinephrine—Hypertension—Sorafenib—kidney cancer	0.000468	0.00201	CcSEcCtD
Epinephrine—Insomnia—Everolimus—kidney cancer	0.000461	0.00198	CcSEcCtD
Epinephrine—Paraesthesia—Vinblastine—kidney cancer	0.000459	0.00197	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000458	0.00197	CcSEcCtD
Epinephrine—Paraesthesia—Everolimus—kidney cancer	0.000457	0.00196	CcSEcCtD
Epinephrine—Hyperglycaemia—Paclitaxel—kidney cancer	0.000453	0.00195	CcSEcCtD
Epinephrine—Somnolence—Everolimus—kidney cancer	0.000453	0.00195	CcSEcCtD
Epinephrine—Dizziness—Temsirolimus—kidney cancer	0.000453	0.00195	CcSEcCtD
Epinephrine—Hypertension—Sunitinib—kidney cancer	0.00045	0.00193	CcSEcCtD
Epinephrine—Insomnia—Erlotinib—kidney cancer	0.000444	0.00191	CcSEcCtD
Epinephrine—Chest pain—Sunitinib—kidney cancer	0.000444	0.00191	CcSEcCtD
Epinephrine—Mental disorder—Vincristine—kidney cancer	0.000444	0.00191	CcSEcCtD
Epinephrine—Acute coronary syndrome—Paclitaxel—kidney cancer	0.000442	0.0019	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000441	0.00189	CcSEcCtD
Epinephrine—Renal failure—Paclitaxel—kidney cancer	0.00044	0.00189	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Everolimus—kidney cancer	0.00044	0.00189	CcSEcCtD
Epinephrine—Myocardial infarction—Paclitaxel—kidney cancer	0.000439	0.00189	CcSEcCtD
Epinephrine—Vomiting—Temsirolimus—kidney cancer	0.000435	0.00187	CcSEcCtD
Epinephrine—Hypokalaemia—Capecitabine—kidney cancer	0.000434	0.00187	CcSEcCtD
Epinephrine—Nervous system disorder—Sorafenib—kidney cancer	0.000434	0.00186	CcSEcCtD
Epinephrine—Skin disorder—Sorafenib—kidney cancer	0.000429	0.00184	CcSEcCtD
Epinephrine—Arrhythmia—Gemcitabine—kidney cancer	0.000429	0.00184	CcSEcCtD
Epinephrine—Dizziness—Pazopanib—kidney cancer	0.000427	0.00183	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000424	0.00182	CcSEcCtD
Epinephrine—Erythema—Gemcitabine—kidney cancer	0.000418	0.0018	CcSEcCtD
Epinephrine—Nervous system disorder—Sunitinib—kidney cancer	0.000417	0.00179	CcSEcCtD
Epinephrine—Skin disorder—Sunitinib—kidney cancer	0.000413	0.00178	CcSEcCtD
Epinephrine—Vomiting—Pazopanib—kidney cancer	0.00041	0.00176	CcSEcCtD
Epinephrine—Nausea—Temsirolimus—kidney cancer	0.000407	0.00175	CcSEcCtD
Epinephrine—Agitation—Vincristine—kidney cancer	0.000405	0.00174	CcSEcCtD
Epinephrine—Skin exfoliation—Doxorubicin—kidney cancer	0.000405	0.00174	CcSEcCtD
Epinephrine—Haemoglobin—Paclitaxel—kidney cancer	0.000404	0.00174	CcSEcCtD
Epinephrine—Haemorrhage—Paclitaxel—kidney cancer	0.000402	0.00173	CcSEcCtD
Epinephrine—Sweating increased—Capecitabine—kidney cancer	0.000402	0.00173	CcSEcCtD
Epinephrine—Hypoaesthesia—Paclitaxel—kidney cancer	0.0004	0.00172	CcSEcCtD
Epinephrine—Insomnia—Sunitinib—kidney cancer	0.000385	0.00165	CcSEcCtD
Epinephrine—Nausea—Pazopanib—kidney cancer	0.000383	0.00165	CcSEcCtD
Epinephrine—Paraesthesia—Sunitinib—kidney cancer	0.000382	0.00164	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000382	0.00164	CcSEcCtD
Epinephrine—Hypertension—Vincristine—kidney cancer	0.000381	0.00164	CcSEcCtD
Epinephrine—Pulmonary oedema—Doxorubicin—kidney cancer	0.000377	0.00162	CcSEcCtD
Epinephrine—Flushing—Paclitaxel—kidney cancer	0.000373	0.0016	CcSEcCtD
Epinephrine—Hyperglycaemia—Capecitabine—kidney cancer	0.000372	0.0016	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000367	0.00158	CcSEcCtD
Epinephrine—Acute coronary syndrome—Capecitabine—kidney cancer	0.000363	0.00156	CcSEcCtD
Epinephrine—Renal failure—Capecitabine—kidney cancer	0.000361	0.00155	CcSEcCtD
Epinephrine—Hypertension—Gemcitabine—kidney cancer	0.000361	0.00155	CcSEcCtD
Epinephrine—Myocardial infarction—Capecitabine—kidney cancer	0.00036	0.00155	CcSEcCtD
Epinephrine—Arrhythmia—Paclitaxel—kidney cancer	0.000359	0.00154	CcSEcCtD
Epinephrine—Chest pain—Gemcitabine—kidney cancer	0.000356	0.00153	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000354	0.00152	CcSEcCtD
Epinephrine—Nervous system disorder—Vincristine—kidney cancer	0.000353	0.00152	CcSEcCtD
Epinephrine—Mental disorder—Paclitaxel—kidney cancer	0.000352	0.00151	CcSEcCtD
Epinephrine—Isoprenaline—CYP1A1—kidney cancer	0.000351	0.051	CrCbGaD
Epinephrine—Erythema—Paclitaxel—kidney cancer	0.00035	0.0015	CcSEcCtD
Epinephrine—Hyperhidrosis—Vincristine—kidney cancer	0.000348	0.00149	CcSEcCtD
Epinephrine—Tension—Paclitaxel—kidney cancer	0.000344	0.00148	CcSEcCtD
Epinephrine—Nervousness—Paclitaxel—kidney cancer	0.00034	0.00146	CcSEcCtD
Epinephrine—Dizziness—Vinblastine—kidney cancer	0.000338	0.00145	CcSEcCtD
Epinephrine—Dizziness—Everolimus—kidney cancer	0.000337	0.00145	CcSEcCtD
Epinephrine—Nervous system disorder—Gemcitabine—kidney cancer	0.000335	0.00144	CcSEcCtD
Epinephrine—Haemoglobin—Capecitabine—kidney cancer	0.000332	0.00143	CcSEcCtD
Epinephrine—Skin disorder—Gemcitabine—kidney cancer	0.000332	0.00142	CcSEcCtD
Epinephrine—Haemorrhage—Capecitabine—kidney cancer	0.00033	0.00142	CcSEcCtD
Epinephrine—Hyperhidrosis—Gemcitabine—kidney cancer	0.00033	0.00142	CcSEcCtD
Epinephrine—Hypoaesthesia—Capecitabine—kidney cancer	0.000328	0.00141	CcSEcCtD
Epinephrine—Insomnia—Vincristine—kidney cancer	0.000325	0.0014	CcSEcCtD
Epinephrine—Vomiting—Vinblastine—kidney cancer	0.000325	0.0014	CcSEcCtD
Epinephrine—Dizziness—Erlotinib—kidney cancer	0.000325	0.0014	CcSEcCtD
Epinephrine—Vomiting—Everolimus—kidney cancer	0.000324	0.00139	CcSEcCtD
Epinephrine—Renal impairment—Doxorubicin—kidney cancer	0.000323	0.00139	CcSEcCtD
Epinephrine—Paraesthesia—Vincristine—kidney cancer	0.000323	0.00139	CcSEcCtD
Epinephrine—Agitation—Paclitaxel—kidney cancer	0.000322	0.00138	CcSEcCtD
Epinephrine—Hypoglycaemia—Doxorubicin—kidney cancer	0.000315	0.00135	CcSEcCtD
Epinephrine—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000314	0.00135	CcSEcCtD
Epinephrine—Vomiting—Erlotinib—kidney cancer	0.000312	0.00134	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Vincristine—kidney cancer	0.000311	0.00133	CcSEcCtD
Epinephrine—Palpitations—Paclitaxel—kidney cancer	0.000309	0.00133	CcSEcCtD
Epinephrine—Insomnia—Gemcitabine—kidney cancer	0.000309	0.00133	CcSEcCtD
Epinephrine—Paraesthesia—Gemcitabine—kidney cancer	0.000307	0.00132	CcSEcCtD
Epinephrine—Flushing—Capecitabine—kidney cancer	0.000306	0.00132	CcSEcCtD
Epinephrine—Nausea—Vinblastine—kidney cancer	0.000304	0.0013	CcSEcCtD
Epinephrine—Somnolence—Gemcitabine—kidney cancer	0.000303	0.0013	CcSEcCtD
Epinephrine—Nausea—Everolimus—kidney cancer	0.000303	0.0013	CcSEcCtD
Epinephrine—Hypertension—Paclitaxel—kidney cancer	0.000302	0.0013	CcSEcCtD
Epinephrine—Chest pain—Paclitaxel—kidney cancer	0.000298	0.00128	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000296	0.00127	CcSEcCtD
Epinephrine—Arrhythmia—Capecitabine—kidney cancer	0.000295	0.00127	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000295	0.00127	CcSEcCtD
Epinephrine—Dizziness—Sorafenib—kidney cancer	0.000292	0.00126	CcSEcCtD
Epinephrine—Nausea—Erlotinib—kidney cancer	0.000292	0.00125	CcSEcCtD
Epinephrine—Mental disorder—Capecitabine—kidney cancer	0.000289	0.00124	CcSEcCtD
Epinephrine—Erythema—Capecitabine—kidney cancer	0.000287	0.00123	CcSEcCtD
Epinephrine—Dizziness—Sunitinib—kidney cancer	0.000281	0.00121	CcSEcCtD
Epinephrine—Vomiting—Sorafenib—kidney cancer	0.000281	0.00121	CcSEcCtD
Epinephrine—Nervous system disorder—Paclitaxel—kidney cancer	0.00028	0.0012	CcSEcCtD
Epinephrine—Hypokalaemia—Doxorubicin—kidney cancer	0.00028	0.0012	CcSEcCtD
Epinephrine—Tachycardia—Paclitaxel—kidney cancer	0.000279	0.0012	CcSEcCtD
Epinephrine—Skin disorder—Paclitaxel—kidney cancer	0.000278	0.00119	CcSEcCtD
Epinephrine—Hyperhidrosis—Paclitaxel—kidney cancer	0.000276	0.00119	CcSEcCtD
Epinephrine—Vomiting—Sunitinib—kidney cancer	0.00027	0.00116	CcSEcCtD
Epinephrine—Nausea—Sorafenib—kidney cancer	0.000263	0.00113	CcSEcCtD
Epinephrine—Insomnia—Paclitaxel—kidney cancer	0.000258	0.00111	CcSEcCtD
Epinephrine—Paraesthesia—Paclitaxel—kidney cancer	0.000257	0.0011	CcSEcCtD
Epinephrine—Vomiting—Dactinomycin—kidney cancer	0.000256	0.0011	CcSEcCtD
Epinephrine—Somnolence—Paclitaxel—kidney cancer	0.000254	0.00109	CcSEcCtD
Epinephrine—Palpitations—Capecitabine—kidney cancer	0.000254	0.00109	CcSEcCtD
Epinephrine—Nausea—Sunitinib—kidney cancer	0.000253	0.00109	CcSEcCtD
Epinephrine—Hypertension—Capecitabine—kidney cancer	0.000248	0.00107	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000247	0.00106	CcSEcCtD
Epinephrine—Chest pain—Capecitabine—kidney cancer	0.000245	0.00105	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000243	0.00104	CcSEcCtD
Epinephrine—Hyperglycaemia—Doxorubicin—kidney cancer	0.00024	0.00103	CcSEcCtD
Epinephrine—Nausea—Dactinomycin—kidney cancer	0.000239	0.00103	CcSEcCtD
Epinephrine—Dizziness—Vincristine—kidney cancer	0.000238	0.00102	CcSEcCtD
Epinephrine—Drowsiness—Doxorubicin—kidney cancer	0.000237	0.00102	CcSEcCtD
Epinephrine—Renal failure—Doxorubicin—kidney cancer	0.000233	0.001	CcSEcCtD
Epinephrine—Nervous system disorder—Capecitabine—kidney cancer	0.00023	0.000988	CcSEcCtD
Epinephrine—Tachycardia—Capecitabine—kidney cancer	0.000229	0.000983	CcSEcCtD
Epinephrine—Vomiting—Vincristine—kidney cancer	0.000229	0.000983	CcSEcCtD
Epinephrine—Skin disorder—Capecitabine—kidney cancer	0.000228	0.000979	CcSEcCtD
Epinephrine—Sweating—Doxorubicin—kidney cancer	0.000227	0.000976	CcSEcCtD
Epinephrine—Hyperhidrosis—Capecitabine—kidney cancer	0.000227	0.000974	CcSEcCtD
Epinephrine—Vomiting—Gemcitabine—kidney cancer	0.000217	0.000932	CcSEcCtD
Epinephrine—Haemoglobin—Doxorubicin—kidney cancer	0.000214	0.000919	CcSEcCtD
Epinephrine—Nausea—Vincristine—kidney cancer	0.000214	0.000918	CcSEcCtD
Epinephrine—Haemorrhage—Doxorubicin—kidney cancer	0.000213	0.000914	CcSEcCtD
Epinephrine—Insomnia—Capecitabine—kidney cancer	0.000212	0.000911	CcSEcCtD
Epinephrine—Hypoaesthesia—Doxorubicin—kidney cancer	0.000212	0.00091	CcSEcCtD
Epinephrine—Paraesthesia—Capecitabine—kidney cancer	0.000211	0.000905	CcSEcCtD
Epinephrine—Nausea—Gemcitabine—kidney cancer	0.000203	0.000871	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000202	0.00087	CcSEcCtD
Epinephrine—Flushing—Doxorubicin—kidney cancer	0.000197	0.000848	CcSEcCtD
Epinephrine—Arrhythmia—Doxorubicin—kidney cancer	0.00019	0.000817	CcSEcCtD
Epinephrine—Dizziness—Paclitaxel—kidney cancer	0.000189	0.000812	CcSEcCtD
Epinephrine—Mental disorder—Doxorubicin—kidney cancer	0.000186	0.000801	CcSEcCtD
Epinephrine—Erythema—Doxorubicin—kidney cancer	0.000185	0.000796	CcSEcCtD
Epinephrine—Tension—Doxorubicin—kidney cancer	0.000182	0.000781	CcSEcCtD
Epinephrine—Vomiting—Paclitaxel—kidney cancer	0.000182	0.000781	CcSEcCtD
Epinephrine—Nervousness—Doxorubicin—kidney cancer	0.00018	0.000773	CcSEcCtD
Epinephrine—Agitation—Doxorubicin—kidney cancer	0.00017	0.000731	CcSEcCtD
Epinephrine—Nausea—Paclitaxel—kidney cancer	0.00017	0.000729	CcSEcCtD
Epinephrine—Palpitations—Doxorubicin—kidney cancer	0.000164	0.000703	CcSEcCtD
Epinephrine—Hypertension—Doxorubicin—kidney cancer	0.00016	0.000687	CcSEcCtD
Epinephrine—Chest pain—Doxorubicin—kidney cancer	0.000158	0.000678	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000157	0.000673	CcSEcCtD
Epinephrine—Dizziness—Capecitabine—kidney cancer	0.000155	0.000666	CcSEcCtD
Epinephrine—Vomiting—Capecitabine—kidney cancer	0.000149	0.000641	CcSEcCtD
Epinephrine—Nervous system disorder—Doxorubicin—kidney cancer	0.000148	0.000637	CcSEcCtD
Epinephrine—Tachycardia—Doxorubicin—kidney cancer	0.000148	0.000634	CcSEcCtD
Epinephrine—Skin disorder—Doxorubicin—kidney cancer	0.000147	0.000631	CcSEcCtD
Epinephrine—Hyperhidrosis—Doxorubicin—kidney cancer	0.000146	0.000628	CcSEcCtD
Epinephrine—Nausea—Capecitabine—kidney cancer	0.000139	0.000598	CcSEcCtD
Epinephrine—Insomnia—Doxorubicin—kidney cancer	0.000137	0.000587	CcSEcCtD
Epinephrine—Paraesthesia—Doxorubicin—kidney cancer	0.000136	0.000583	CcSEcCtD
Epinephrine—Somnolence—Doxorubicin—kidney cancer	0.000134	0.000577	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000131	0.000561	CcSEcCtD
Epinephrine—Dizziness—Doxorubicin—kidney cancer	0.0001	0.000429	CcSEcCtD
Epinephrine—Vomiting—Doxorubicin—kidney cancer	9.61e-05	0.000413	CcSEcCtD
Epinephrine—Nausea—Doxorubicin—kidney cancer	8.98e-05	0.000386	CcSEcCtD
Epinephrine—ADRA2C—Signaling Pathways—APC—kidney cancer	7.79e-06	3.77e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—BRAF—kidney cancer	7.74e-06	3.75e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—HIF1A—kidney cancer	7.73e-06	3.74e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TSC2—kidney cancer	7.71e-06	3.73e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—BCHE—kidney cancer	7.69e-06	3.72e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—MAPK1—kidney cancer	7.67e-06	3.71e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—APC—kidney cancer	7.67e-06	3.71e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—KIT—kidney cancer	7.67e-06	3.71e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—MAPK1—kidney cancer	7.63e-06	3.69e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—SLC5A5—kidney cancer	7.6e-06	3.68e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—MAPK1—kidney cancer	7.6e-06	3.68e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—IL2—kidney cancer	7.54e-06	3.65e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—MAPK1—kidney cancer	7.5e-06	3.63e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ITPR2—kidney cancer	7.47e-06	3.62e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—MAPK3—kidney cancer	7.46e-06	3.61e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—POMC—kidney cancer	7.41e-06	3.59e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—KDR—kidney cancer	7.39e-06	3.58e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—MAPK3—kidney cancer	7.34e-06	3.55e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—SLC2A1—kidney cancer	7.34e-06	3.55e-05	CbGpPWpGaD
Epinephrine—ADRB1—GPCR downstream signaling—PIK3CA—kidney cancer	7.33e-06	3.55e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—BRAF—kidney cancer	7.32e-06	3.54e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—PIK3CA—kidney cancer	7.3e-06	3.54e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—POMC—kidney cancer	7.3e-06	3.53e-05	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—PTGS2—kidney cancer	7.27e-06	3.52e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.27e-06	3.52e-05	CbGpPWpGaD
Epinephrine—ADRA2B—GPCR downstream signaling—PIK3CA—kidney cancer	7.26e-06	3.51e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—RAF1—kidney cancer	7.25e-06	3.51e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—KRAS—kidney cancer	7.24e-06	3.51e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—RELA—kidney cancer	7.22e-06	3.49e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—KRAS—kidney cancer	7.21e-06	3.49e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—BRAF—kidney cancer	7.21e-06	3.49e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—POMC—kidney cancer	7.2e-06	3.49e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—HIF1A—kidney cancer	7.18e-06	3.48e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—KRAS—kidney cancer	7.18e-06	3.47e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—ERBB2—kidney cancer	7.17e-06	3.47e-05	CbGpPWpGaD
Epinephrine—ADRB2—GPCR downstream signaling—PIK3CA—kidney cancer	7.17e-06	3.47e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TSC2—kidney cancer	7.16e-06	3.47e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—GSTP1—kidney cancer	7.16e-06	3.47e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	7.12e-06	3.45e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—MAPK1—kidney cancer	7.1e-06	3.44e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—KRAS—kidney cancer	7.09e-06	3.43e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MTOR—kidney cancer	7.08e-06	3.43e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—PTGS2—kidney cancer	7.07e-06	3.42e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—MAPK1—kidney cancer	6.99e-06	3.38e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—KDR—kidney cancer	6.87e-06	3.32e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ACHE—kidney cancer	6.82e-06	3.3e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GSTT1—kidney cancer	6.82e-06	3.3e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—APC—kidney cancer	6.81e-06	3.3e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—KIT—kidney cancer	6.81e-06	3.3e-05	CbGpPWpGaD
Epinephrine—ADRA2C—GPCR downstream signaling—PIK3CA—kidney cancer	6.78e-06	3.28e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—ABCB1—kidney cancer	6.78e-06	3.28e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—PTGS2—kidney cancer	6.78e-06	3.28e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—KRAS—kidney cancer	6.7e-06	3.25e-05	CbGpPWpGaD
Epinephrine—ADRA1B—GPCR downstream signaling—PIK3CA—kidney cancer	6.68e-06	3.23e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—PIK3CA—kidney cancer	6.65e-06	3.22e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—CDKN1B—kidney cancer	6.64e-06	3.21e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—PIK3CA—kidney cancer	6.62e-06	3.21e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—RAF1—kidney cancer	6.61e-06	3.2e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—KRAS—kidney cancer	6.6e-06	3.19e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—PIK3CA—kidney cancer	6.59e-06	3.19e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—GSTM1—kidney cancer	6.58e-06	3.19e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—RELA—kidney cancer	6.58e-06	3.18e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—RAF1—kidney cancer	6.54e-06	3.17e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—ERBB2—kidney cancer	6.53e-06	3.16e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—MAPK3—kidney cancer	6.52e-06	3.16e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—RELA—kidney cancer	6.52e-06	3.15e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—PIK3CA—kidney cancer	6.51e-06	3.15e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—IL2—kidney cancer	6.5e-06	3.15e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—POMC—kidney cancer	6.48e-06	3.14e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—ERBB2—kidney cancer	6.48e-06	3.13e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—RAF1—kidney cancer	6.46e-06	3.13e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—SCARB1—kidney cancer	6.45e-06	3.12e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MTOR—kidney cancer	6.45e-06	3.12e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—RELA—kidney cancer	6.43e-06	3.11e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—TP53—kidney cancer	6.41e-06	3.1e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—BRAF—kidney cancer	6.4e-06	3.1e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—ERBB2—kidney cancer	6.39e-06	3.09e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MTOR—kidney cancer	6.39e-06	3.09e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PTGS1—kidney cancer	6.39e-06	3.09e-05	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—PTEN—kidney cancer	6.34e-06	3.07e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—CCND1—kidney cancer	6.34e-06	3.07e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—APC—kidney cancer	6.33e-06	3.06e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—KIT—kidney cancer	6.33e-06	3.06e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—JUN—kidney cancer	6.32e-06	3.06e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MTOR—kidney cancer	6.31e-06	3.05e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—CTNNB1—kidney cancer	6.28e-06	3.04e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PSMD7—kidney cancer	6.26e-06	3.03e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—CYP1A1—kidney cancer	6.24e-06	3.02e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	6.21e-06	3.01e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	6.21e-06	3e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—PTEN—kidney cancer	6.17e-06	2.99e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—PIK3CA—kidney cancer	6.16e-06	2.98e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—GSTP1—kidney cancer	6.12e-06	2.96e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—PTEN—kidney cancer	6.12e-06	2.96e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—RAF1—kidney cancer	6.11e-06	2.96e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—RELA—kidney cancer	6.09e-06	2.95e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—PIK3CA—kidney cancer	6.06e-06	2.93e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	6.06e-06	2.93e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CDKN1B—kidney cancer	6.05e-06	2.93e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—ERBB2—kidney cancer	6.05e-06	2.93e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—POMC—kidney cancer	6.02e-06	2.92e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—RAF1—kidney cancer	6.02e-06	2.91e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CDKN1B—kidney cancer	6e-06	2.9e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—RELA—kidney cancer	5.99e-06	2.9e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MTOR—kidney cancer	5.97e-06	2.89e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—ERBB2—kidney cancer	5.95e-06	2.88e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—BRAF—kidney cancer	5.95e-06	2.88e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—BCHE—kidney cancer	5.94e-06	2.87e-05	CbGpPWpGaD
Epinephrine—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	5.93e-06	2.87e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—IL2—kidney cancer	5.92e-06	2.87e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CDKN1B—kidney cancer	5.92e-06	2.87e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—PTEN—kidney cancer	5.91e-06	2.86e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MTOR—kidney cancer	5.87e-06	2.84e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—IL2—kidney cancer	5.87e-06	2.84e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—SLC5A5—kidney cancer	5.87e-06	2.84e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	5.86e-06	2.84e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—ABCB1—kidney cancer	5.79e-06	2.8e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—IL2—kidney cancer	5.79e-06	2.8e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CCND1—kidney cancer	5.77e-06	2.79e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	5.77e-06	2.79e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—JUN—kidney cancer	5.76e-06	2.79e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PTGS2—kidney cancer	5.75e-06	2.78e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CCND1—kidney cancer	5.72e-06	2.77e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CTNNB1—kidney cancer	5.72e-06	2.77e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—JUN—kidney cancer	5.71e-06	2.76e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CTNNB1—kidney cancer	5.67e-06	2.74e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—SLC2A1—kidney cancer	5.66e-06	2.74e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CCND1—kidney cancer	5.65e-06	2.73e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—JUN—kidney cancer	5.64e-06	2.73e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—GSTM1—kidney cancer	5.63e-06	2.72e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CDKN1B—kidney cancer	5.6e-06	2.71e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CTNNB1—kidney cancer	5.59e-06	2.71e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PTEN—kidney cancer	5.57e-06	2.7e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—VEGFA—kidney cancer	5.52e-06	2.67e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PTEN—kidney cancer	5.52e-06	2.67e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CDKN1B—kidney cancer	5.51e-06	2.67e-05	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	5.51e-06	2.67e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IL2—kidney cancer	5.48e-06	2.65e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PTEN—kidney cancer	5.45e-06	2.64e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	5.45e-06	2.64e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IL2—kidney cancer	5.39e-06	2.61e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	5.38e-06	2.61e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—RAF1—kidney cancer	5.34e-06	2.59e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CCND1—kidney cancer	5.34e-06	2.59e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CYP1A1—kidney cancer	5.33e-06	2.58e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—JUN—kidney cancer	5.33e-06	2.58e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—RELA—kidney cancer	5.32e-06	2.58e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	5.29e-06	2.56e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	5.29e-06	2.56e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CCND1—kidney cancer	5.26e-06	2.55e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—JUN—kidney cancer	5.25e-06	2.54e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MAPK3—kidney cancer	5.23e-06	2.53e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MTOR—kidney cancer	5.22e-06	2.53e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	5.21e-06	2.52e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PTEN—kidney cancer	5.16e-06	2.5e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.13e-06	2.48e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MYC—kidney cancer	5.08e-06	2.46e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PTEN—kidney cancer	5.08e-06	2.46e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—VEGFA—kidney cancer	5.03e-06	2.44e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PTEN—kidney cancer	5.01e-06	2.43e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	5e-06	2.42e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	4.99e-06	2.41e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MAPK1—kidney cancer	4.97e-06	2.41e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—RAF1—kidney cancer	4.97e-06	2.4e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—RELA—kidney cancer	4.94e-06	2.39e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—VEGFA—kidney cancer	4.92e-06	2.38e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	4.91e-06	2.38e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	4.9e-06	2.37e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MTOR—kidney cancer	4.85e-06	2.35e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IL2—kidney cancer	4.79e-06	2.32e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MAPK3—kidney cancer	4.76e-06	2.3e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GSTP1—kidney cancer	4.72e-06	2.29e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	4.72e-06	2.28e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—KRAS—kidney cancer	4.7e-06	2.27e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CCND1—kidney cancer	4.67e-06	2.26e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—JUN—kidney cancer	4.66e-06	2.26e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	4.66e-06	2.25e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MAPK3—kidney cancer	4.66e-06	2.25e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—POMC—kidney cancer	4.65e-06	2.25e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MYC—kidney cancer	4.63e-06	2.24e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	4.63e-06	2.24e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MYC—kidney cancer	4.59e-06	2.22e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	4.58e-06	2.22e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	4.55e-06	2.2e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MAPK1—kidney cancer	4.53e-06	2.19e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MYC—kidney cancer	4.53e-06	2.19e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PTEN—kidney cancer	4.51e-06	2.18e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	4.49e-06	2.17e-05	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—PIK3CA—kidney cancer	4.47e-06	2.17e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ABCB1—kidney cancer	4.47e-06	2.16e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IL2—kidney cancer	4.45e-06	2.16e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MAPK1—kidney cancer	4.43e-06	2.15e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	4.41e-06	2.13e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.38e-06	2.12e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—PIK3CA—kidney cancer	4.35e-06	2.11e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GSTM1—kidney cancer	4.34e-06	2.1e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CCND1—kidney cancer	4.34e-06	2.1e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	4.34e-06	2.1e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—JUN—kidney cancer	4.33e-06	2.1e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—PIK3CA—kidney cancer	4.31e-06	2.09e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	4.3e-06	2.08e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MYC—kidney cancer	4.29e-06	2.07e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—KRAS—kidney cancer	4.28e-06	2.07e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—KRAS—kidney cancer	4.24e-06	2.05e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MYC—kidney cancer	4.22e-06	2.04e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	4.19e-06	2.03e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PTEN—kidney cancer	4.19e-06	2.03e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—KRAS—kidney cancer	4.19e-06	2.03e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TP53—kidney cancer	4.17e-06	2.02e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—PIK3CA—kidney cancer	4.17e-06	2.02e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	4.13e-06	2e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CYP1A1—kidney cancer	4.12e-06	1.99e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	4.07e-06	1.97e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—POMC—kidney cancer	3.98e-06	1.92e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—KRAS—kidney cancer	3.96e-06	1.92e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PIK3CA—kidney cancer	3.93e-06	1.9e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—KRAS—kidney cancer	3.9e-06	1.89e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	3.9e-06	1.89e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	3.85e-06	1.86e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PIK3CA—kidney cancer	3.85e-06	1.86e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TP53—kidney cancer	3.8e-06	1.84e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	3.78e-06	1.83e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TP53—kidney cancer	3.77e-06	1.82e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MYC—kidney cancer	3.75e-06	1.81e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TP53—kidney cancer	3.72e-06	1.8e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PTGS2—kidney cancer	3.71e-06	1.8e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	3.67e-06	1.77e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	3.64e-06	1.76e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	3.58e-06	1.73e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	3.58e-06	1.73e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PIK3CA—kidney cancer	3.53e-06	1.71e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TP53—kidney cancer	3.52e-06	1.7e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MYC—kidney cancer	3.48e-06	1.69e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TP53—kidney cancer	3.46e-06	1.68e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—KRAS—kidney cancer	3.46e-06	1.68e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	3.41e-06	1.65e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PTEN—kidney cancer	3.24e-06	1.57e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—KRAS—kidney cancer	3.22e-06	1.56e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	3.18e-06	1.54e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PTGS2—kidney cancer	3.17e-06	1.53e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TP53—kidney cancer	3.08e-06	1.49e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—POMC—kidney cancer	3.07e-06	1.49e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	2.96e-06	1.43e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TP53—kidney cancer	2.86e-06	1.38e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PTEN—kidney cancer	2.77e-06	1.34e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PTGS2—kidney cancer	2.45e-06	1.18e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PIK3CA—kidney cancer	2.28e-06	1.11e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PTEN—kidney cancer	2.13e-06	1.03e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.95e-06	9.44e-06	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.51e-06	7.29e-06	CbGpPWpGaD
